Veru stock price target lowered to $20 at Raymond James on obesity drug

Raymond James lowered its price target on Veru (VERU) to $20 from $30, while maintaining an Outperform rating, following the company's significant Q3 2025 EPS miss of -$0.50, a 900% deviation from expectations. Despite this financial setback and ongoing rapid cash burn concerns, Veru reported positive Phase 2b trial results for its Enobosarm obesity program, demonstrating 100% lean mass preservation and reduced weight/fat regain. The company is preparing for an End-of-Phase 2 FDA meeting later this quarter to finalize Phase 3 trial design and is actively pursuing partnerships and financing for the program, presenting a mixed outlook of clinical promise against immediate financial challenges.

Analysis

Veru Inc. (VERU) presents a stark dichotomy between its deteriorating financial position and the promising clinical advancement of its lead asset, Enobosarm. The company reported a significant earnings miss for Q3 2025, with an EPS of -$0.50, a 900% negative deviation from the -$0.05 analyst projection, contributing to a stock decline of over 61% in the past year. Despite a strong liquidity position indicated by a 3.8 current ratio and more cash than debt, the company's rapid cash burn is a material concern. This financial pressure is reflected in Raymond James's decision to lower its price target to $20 from $30. However, the maintenance of an "Outperform" rating highlights the perceived value in Veru's pipeline. The positive Phase 2b trial results for Enobosarm are compelling, demonstrating 100% lean mass preservation when used with semaglutide and a reduction in weight regain after its discontinuation. A key near-term catalyst is the upcoming End-of-Phase 2 meeting with the FDA, which will clarify the regulatory path and cost for the Phase 3 program. The company's selection of a new modified-release oral formulation with extended patent protection further enhances the asset's commercial profile, but its ability to secure partnerships or financing for the expensive next phase remains a critical uncertainty.

Key Decisions for Investors

• Investors should view Veru as a high-risk, catalyst-driven investment, where the significant potential of its Enobosarm obesity program is weighed against substantial financial headwinds, including a severe earnings miss and high cash burn.
• The upcoming End-of-Phase-2 meeting with the FDA is a critical inflection point; its outcome, and any subsequent news on partnerships to fund the Phase 3 program, will be a primary driver of valuation.
• Given the stock's sharp decline and the company's clear need for capital, prospective investors must be prepared for significant volatility and the high probability of shareholder dilution to fund future clinical development.